Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Background Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke
as compared with aspirin alone when treatment is initiated early (≤ 24 hours) after an acute …

The management of patients with stroke is often multidisciplinary, involving various
specialties and healthcare professionals. Given the common shared risk factors for stroke …

Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …

There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are
used to prevent ischemic outcomes in common diseases such as coronary and peripheral …

Stroke is a devastating condition with significant morbidity and mortality worldwide.
Antithrombotic therapy plays a crucial role in both primary and secondary prevention of …

Background People with factor XI deficiency have lower rates of ischaemic stroke than the
general population and infrequent spontaneous bleeding, suggesting that factor XI has a …

Background Individuals with ischemic stroke or transient ischemic attack (TIA) have a high
early risk of ischemic stroke despite dual antiplatelet therapy. The risk of ischemic stroke …

Importance Previous randomized clinical trials did not demonstrate the superiority of
endovascular stenting over aggressive medical management for patients with symptomatic …